Phagos Secures $30M Series A to Advance AI-Driven Phage Therapy Against Antibiotic Resistance in Animal Health

Courtesy: Phagos

Phagos, a biotechnology startup using AI to develop precision phage therapies for livestock, has closed a $30M Series A to combat antimicrobial resistance and expand globally.

In a step toward tackling the global crisis of antimicrobial resistance, biotechnology company Phagos has closed a $30 million Series A round to scale its next-generation phage therapies for animal health. The funding was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter, with participation from Acurio Ventures, Citizen Capital, Entrepreneurs First, Founders Capital, and Station F.

The fresh capital will propel the company’s international expansion, bolster its AI-driven phage discovery platform, and accelerate the commercial deployment of veterinary treatments designed to reduce antibiotic use in livestock. Phagos is already making headlines for achieving a global regulatory first, becoming the world’s first company authorized to market personalized phage-based veterinary drugs.

Founded in 2021 by Alexandros Pantalis and Dr. Adèle James, Phagos merges microbiology with artificial intelligence to develop precision phage therapies, natural viruses that selectively infect and kill bacteria. The company’s proprietary platform analyzes entire bacterial and phage genomes to predict optimal combinations, allowing scientists to rapidly design targeted, scalable, and personalized treatments.

“We are convinced that phage therapy can transform the history of medicine just as antibiotics did in the last century,” said Pantalis and James. “This funding allows us to accelerate our mission and make phage therapy accessible, effective, and scalable, first in animal health, and ultimately in human health.”

A New Front in the Fight Against AMR

The rise of antimicrobial resistance (AMR) represents one of the greatest threats to global health, responsible for millions of deaths each year and undermining decades of medical and agricultural progress. In livestock alone, one in three antibiotics is now ineffective, driving urgent demand for sustainable alternatives.

Phagos’ technology addresses this gap by offering a biologically precise, antibiotic-free solution. Its early products target major bacterial pathogens such as Salmonella and E. coli, two leading causes of infections in livestock that have direct implications for food safety and productivity.

“Antimicrobial resistance is a defining challenge for global food systems,” said Anne-Valérie Bach, Managing Director at CapAgro. “With its regulatory approval and AI-powered discovery platform, Phagos is leading the way in deploying actionable, sustainable alternatives to antibiotics.”

From Lab to Global Market

Phagos’ recent regulatory milestone has positioned it at the forefront of a rapidly emerging field that bridges biotechnology, AI, and veterinary medicine. With patents filed for its core platform, the company has begun pilot deployments with industry partners across Europe, Asia, and the Americas.

The round also highlights a broader surge of investor interest in phage-based and microbial therapeutics, following recent funding activity in companies such as Proteon Pharmaceuticals, BiomEdit, and Intralytix, all aiming to reshape how animal health is managed in a post-antibiotic era.

Currently, 90% of Phagos’ workforce consists of scientific and technical specialists focused on research, manufacturing, and commercialization. The new investment will allow Phagos to scale up production capacity, expand its R&D team, and enhance its AI engine for discovering new phage-bacteria interactions, paving the way for the company’s future entry into human health applications.

“Phagos’ pioneering platform offers a high-efficiency alternative to antibiotics,” added Rob Kniaz, Founder and Emeritus Partner at Hoxton Ventures. “Its potential to reshape how bacterial infections are treated could establish a new global standard in both animal and human medicine.”

The Road Ahead

With its Series A secured, Phagos is poised to bring precision phage therapy into the mainstream, providing veterinarians and farmers with tools to safeguard animal welfare while protecting public health. As global demand for antibiotic alternatives accelerates, Phagos’ next phase will test whether AI-guided phage therapy can move from niche trials to mainstream veterinary practice, and, ultimately, whether it can redefine how the world fights bacterial infections across species.